Last reviewed · How we verify
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. Secondary objectives focus on evaluating preliminary efficacy through several parameters: XP-006-induced antigen-specific CD4+/CD8+ T cell activation levels, objective remission rate (ORR), complete remission rate (CRR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Details
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | PHASE1 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 20 |
| Start date | Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- B-cell Non-Hodgkin's Lymphoma (B-NHL)
Interventions
- Personalized neoantigen tumor vaccine
Countries
China